Semaglutide reduced body weight, insulin resistance, dyslipidemia, and heart failure markers in obese hamsters with fatty liver disease, while also reducing fructose and alcohol consumption.
Reduced alcohol intakeSemaglutide significantly reduced voluntary alcohol and fructose consumption in obese hamsters, supporting emerging evidence of GLP-1 drug effects on addictive behaviors
What the researchers found
In free-choice diet obese hamsters with MASH and heart failure:
Semaglutide effects:
- Transiently reduced food intake
- Significantly reduced fructose and alcohol consumption
- Significant body weight loss
- Lower HOMA-IR index (improved insulin resistance)
- Improved dyslipidemia (cholesterol problems)
- Improved heart failure with preserved ejection fraction (HFpEF)
- Reduced hepatic fat content only (not full MASH resolution)
Lanifibranor showed similar cardiometabolic benefits but was superior in the liver, significantly improving both MASH and alcohol-related liver disease (MetALD).
Both drugs' effects in hamsters matched what has been observed in human clinical trials, validating the animal model.
Why it matters
Semaglutide is already one of the most prescribed GLP-1 drugs worldwide. This study expands understanding of its benefits beyond weight loss and diabetes to liver disease and heart failure — two of the most serious consequences of obesity. The finding that semaglutide reduces voluntary alcohol consumption is particularly intriguing, as it aligns with emerging human reports of reduced cravings for alcohol and addictive substances on GLP-1 drugs.
How the study worked
Obese hamsters were created using a free-choice diet model that produces human-like lipoprotein metabolism, MASH, and heart failure with preserved ejection fraction. Animals were treated with semaglutide or lanifibranor. Some hamsters were also exposed to ethanol to model chronic alcohol intake and alcohol binge drinking (MetALD model). Metabolic parameters, liver histology, cardiac function, and voluntary consumption behaviors were measured.
What this study cannot tell us
This is an animal study using hamsters, which are chosen for their human-like lipoprotein metabolism but don't perfectly replicate human disease. Dosing and treatment durations in hamsters may not translate directly to humans. Semaglutide reduced liver fat but did not fully resolve MASH, suggesting it may not be sufficient as a standalone liver therapy. The alcohol consumption effects were observed in animals and may not predict human behavior changes.
How to read the evidence
This is a preclinical animal study using a well-validated hamster model. The authors emphasize that the model's results match human clinical trial data, which strengthens translatability. However, animal studies carry inherent limitations and do not replace human clinical evidence.
When this study was published
Published in 2025, this study reflects the latest preclinical research on semaglutide's expanding therapeutic applications. The findings are timely given active clinical trials of GLP-1 drugs for MASH, heart failure, and addictive behaviors.
The bigger picture
GLP-1 receptor agonists like semaglutide are increasingly recognized as multi-system metabolic therapies rather than just diabetes or weight loss drugs. This study adds evidence for their potential in fatty liver disease and heart failure, both of which affect millions of obese individuals. The alcohol consumption reduction finding connects to the growing interest in GLP-1 drugs for addictive behaviors — a potentially transformative application if confirmed in humans.
Questions still open
- Could combining semaglutide with lanifibranor provide both the weight/cardiovascular benefits and the liver-specific improvements that neither drug achieves alone?
- Does semaglutide's reduction of alcohol consumption in hamsters translate to clinical benefits for people with alcohol use disorder?
- Would longer treatment durations with semaglutide eventually resolve MASH, or does it only reduce liver fat without addressing fibrosis?
Common questions
Can semaglutide treat fatty liver disease (MASH)?
Does semaglutide really reduce alcohol cravings?
Read the original research
Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.
European journal of pharmacology, 1003, 177945
Citation
Briand, François; Dubroca, Caroline; Wettstein, Guillaume; Grasset, Estelle; Breyner, Natalia; Bigot, Claire; Assaly, Rana; Broqua, Pierre; Sulpice, Thierry. (2025). Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.. European journal of pharmacology, 1003, 177945. https://doi.org/10.1016/j.ejphar.2025.177945